StockNews.AI
LFCR
StockNews.AI
145 days

Lifecore Biomedical to Report Financial Results for Third Quarter of Fiscal 2025 on April 3, 2025

1. Lifecore Biomedical will report Q3 2025 financial results on April 3. 2. Management will host a webcast to discuss results and corporate updates. 3. Lifecore specializes in the CDMO space for sterile injectable pharmaceutical products. 4. The company has over 40 years of experience in hyaluronic acid manufacturing. 5. Recent developments may indicate future growth in the biopharmaceutical sector.

Earnings
+0.29%Current Return
VS
-2%S&P 500
$6.8303/27 04:22 PM EDTEvent Start
$6.8503/28 10:44 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Bullish?

The upcoming financial results could show positive growth, boosting investor confidence. Historical instances, like recent earnings reports revealing higher-than-expected revenue, often lead to stock price appreciation.

How important is it?

With earnings reports impacting stock valuations, this announcement is significant. Anticipated growth in the biopharma sector aligns with Lifecore’s business focus, enhancing importance.

Why Short Term?

The financial results announcement will have immediate effects on stock sentiment. Similar past events often show short-term volatility around earnings announcements that recede after a few days.

Related Companies

AMGNREGNVRTX
CHASKA, Minn., March 27, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the third quarter of fiscal year 2025 on Thursday, April 3, 2025, after market close. At 4:30 p.m. Eastern Time that day, members of Lifecore’s senior management team will host a webcast to discuss financial results for the quarter and review recent corporate developments. To listen to the live webcast, or access the archived webcast, please visit the Investor Events & Presentations page of Lifecore’s website at: https://ir.lifecore.com/events-presentations. Following the live webcast, an archived version of the webcast will be available on the company’s website for 30 days.    About Lifecore Biomedical Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.

Related News